{
    "20b34e62-97c2-4ca0-bb1d-7824dab0b8bb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "There are no conditions on mental mental health, bodyweight, size of tumours, Karnofsky/ECOG score or Estimated life expectancy that need to be met in order to be eligible for the primary trial ",
        "Label": "Entailment"
    },
    "56530063-b408-47f2-8421-6be825f5559c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "The Interventions in the primary trial are administered through different routes.",
        "Label": "Entailment"
    },
    "64df451c-f868-49e6-9b4e-a325e62ce837": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "the primary trial participants do not receive any vaccines",
        "Label": "Entailment"
    },
    "dc4765a3-6168-4594-969b-3ce5ea7dc02a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934",
        "Label": "Contradiction"
    },
    "aeddc485-09b1-4ddc-9a45-3a8bf0bec2c3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "Over 6 weeks of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 5% reduction in the Percentage of cells with Ki67 expression  ",
        "Label": "Entailment"
    },
    "4ed1c5fd-58e5-4fe8-97b1-59ed509ccb10": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "there are several different instances of cardiac related AE recorded for cohort 1 of the primary trial",
        "Label": "Entailment"
    },
    "571d4650-e64b-4cb2-b719-0d7064e51745": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy",
        "Label": "Contradiction"
    },
    "d7abbd7d-a767-49c0-bc99-1c28074eac21": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "Cohort 1 of the primary trial did not report any Aes, however almost all of cohort 2 candidates suffered at least one ae",
        "Label": "Contradiction"
    },
    "412583db-ce19-451d-a804-3837e4dcaea3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "Coronary artery stenosis are the most common AE recorded in the primary trial",
        "Label": "Contradiction"
    },
    "97acf304-2707-4a1b-81e7-339fde2ed0ee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "patients with Fronto-temporal dementia or Mixed dementia are eligible for the primary trial",
        "Label": "Contradiction"
    },
    "21a5f296-5b3c-4860-be64-77ffb8f76501": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "Both cohorts of the primary trial contained the same number of participants",
        "Label": "Entailment"
    },
    "328417f9-8f45-4114-82d7-9396b6bc578e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "Patients in the primary trial will need to receive one single injection on day 8 of the study.",
        "Label": "Contradiction"
    },
    "5fbee4f6-43fc-45a7-88c4-3dcd5ff21053": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "A patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial",
        "Label": "Entailment"
    },
    "576967ff-d2bb-4d1c-b2a1-8516ceb7a519": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "In the primary trial the placebo intervention and the Memantine intervention are both administered orally, once daily.",
        "Label": "Contradiction"
    },
    "6c29e8c1-36ca-4e6e-b4dc-f1e91b98e546": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "cohort 2 of the primary trial is administered Enzalutamide orally, whereas cohort 1 recieves it by IV",
        "Label": "Contradiction"
    },
    "d35e9b96-20fc-4778-a7db-e87c861c4938": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "More than 1/3 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the study",
        "Label": "Entailment"
    },
    "23f84ae0-fd01-4799-8872-118e22a015e8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "Only three different types of adverse events affected patients in the primary trial, Pancreatitis, Cholelithiasis, Hepatic pain and Febrile neutropenia",
        "Label": "Contradiction"
    },
    "c2aea351-6ce5-4d26-9ba5-2632c6367b93": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "at least one patient in the primary trial suffered several different adverse events",
        "Label": "Entailment"
    },
    "388cc99c-4cb3-4ff9-9496-07f4a6bf6ac7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients administered with testosterone Cream.",
        "Label": "Contradiction"
    },
    "455d059c-c3c4-4a09-be0d-a14b9568a0d2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "cohort 1 of the primary trial is administered PR negative, ER negative and HER- whereas cohort 2 recieves HER2+",
        "Label": "Contradiction"
    },
    "6d37ed53-a6e4-403e-8b93-9954a6486dbc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "laser-assisted fluorescence angiography is used for both interventions in the primary trial.",
        "Label": "Entailment"
    },
    "11cb71ed-1304-42f0-b416-3679c3e9e1b3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention, Cohort 2 will instead receive a regular dosage of radiotherapy",
        "Label": "Contradiction"
    },
    "9349c7c8-7771-4dfc-8981-3c8d84ac5236": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial.",
        "Label": "Entailment"
    },
    "4e91cee2-910e-4f08-8a85-1f13545391c3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "Every participant in the primary trial recieves the same intervention, regardless of whether or not they have cancer.",
        "Label": "Entailment"
    },
    "18c281a1-43bd-47f5-9534-feddfcf0a282": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency, however cohort 2 includes three extra treatment cycles of these particular drugs",
        "Label": "Contradiction"
    },
    "711fdd40-52ec-401c-90fc-5a11de547ab6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "eating disorders were not common for the primary trial candidates",
        "Label": "Entailment"
    },
    "439b1eca-f583-4a2b-bd8e-0baae97b4c15": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "Several of the patients in the primary trial experienced the no pain whatsoever during the 10 weeks of the study.",
        "Label": "Contradiction"
    },
    "f53c5344-36d7-459f-9f84-300e19decced": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "All Patients receiving the placebo intervention in the primary trial experienced emesis ",
        "Label": "Contradiction"
    },
    "99433bba-fce5-4b0a-a076-1f699b51472d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "several of the primary trial candidates are administered 1000 mcg of talazoparib daily, as part of the intervention",
        "Label": "Contradiction"
    },
    "135763e3-70fd-478d-991c-717d6ed55bb3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, however cohort 1 is administered CUDC-101 more often.",
        "Label": "Entailment"
    },
    "6a3053ef-4495-4c18-9da7-68cf5ed254e0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "Every patient in the primary trial is receives a dose of 100 to 1600 \u00ac\u00a8\u00ac\u00b5g fentanyl sublingual spray during radiation therapy",
        "Label": "Contradiction"
    },
    "f1f9d4b4-4877-49ad-a2e2-f53efbe40ef9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "All but one of the patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event, and less than half the patients suffered serious Treatment-Emergent Adverse Events.",
        "Label": "Entailment"
    },
    "cb36e435-6dc9-4e7b-939b-9da6ceef2a49": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "The placebo and Trabectedin intervention in the primary trial are both administered through a 3-hour intravenous infusion on a bi-weekly basis.",
        "Label": "Contradiction"
    },
    "42c38d71-6a83-4967-ad81-ec38c6b5aafd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "cohort 2 of the primary trial is administered twice the dose of Enzalutamide as cohort 1",
        "Label": "Entailment"
    },
    "32cc173a-b271-47c9-997d-df17ce1c7494": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "None of the individual adverse event types recorded in the primary trial affected more than one patient",
        "Label": "Contradiction"
    },
    "b742bc02-cd24-4ae7-b8b8-2a57bbd60d14": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "Patients can not have a history of abdominal fistula, gastrointestinal perforation,Postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial",
        "Label": "Contradiction"
    },
    "04178e95-d808-4a96-ab85-61eb52c17720": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "a total of 35 patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event.",
        "Label": "Contradiction"
    },
    "18d3b58f-42ca-4178-adb6-4a5f0c9fafde": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "None of the patients in the primary trial experienced the worst pain imaginable for 10 weeks.",
        "Label": "Entailment"
    },
    "f58fda4c-f4fd-44a7-8a0f-5d3a16929709": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "one patient in the primary trial had an incident where a surgical incision reopened after the surgery.",
        "Label": "Entailment"
    },
    "e52afcaa-e5d8-4a1f-ae39-8572a64b0aee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "The AZD0530 175 mg group of the primary trial experienced a more significant Percentage Change in betaCTX at week 4 than the Zoledronic Acid 4 mg group.",
        "Label": "Entailment"
    },
    "96042d49-2f5a-44af-8899-2d5ba24c0f6f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "less than 10% of the primary trial participants had a Reduction in circulating tumor cells Following months of High-dose Chemotherapy With Purged Autologous Stem Cell Products",
        "Label": "Contradiction"
    },
    "ea3a7d64-b464-4633-a198-794a4a45b201": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "Results from the primary trial show that tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces Ki67 Expression in Tumors by 40% on average.",
        "Label": "Entailment"
    },
    "58165e03-4aa6-4d0c-8256-dbc92ee900c4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "CAPECITABINE was administered orally every day, to every patient in cohort 2 of the primary trial for the first 21-day cycle",
        "Label": "Contradiction"
    },
    "8f078a17-14cd-4bbc-a9b6-b377ffa077b5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "There was at least 1 recorded gastro-intestinal adverse event and 2 or more psychiatric events in the primary trial",
        "Label": "Contradiction"
    },
    "6e1489a6-3a42-4b52-b690-fb1dd8892749": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "The all recorded Aes in the primary trial occurred to cohort 1 patients",
        "Label": "Entailment"
    },
    "cbc96b9d-b39c-4fbe-b8a7-e7df7490881b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "13% of the primary trial participants with PR+ Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed HER2+ Metastases",
        "Label": "Contradiction"
    },
    "af0e8d9b-f748-424d-a4e7-6bb3bf0ee7a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "African-american patients can participate in the primary trial.",
        "Label": "Entailment"
    },
    "2bd78232-4872-4d66-ade9-836190b86e1d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "A patient diagnosed with a neoplastic meningitis could be eligible for the primary trial",
        "Label": "Contradiction"
    },
    "80a26581-a95c-4c22-864f-93425b1fc165": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention, regardless of cancer type.",
        "Label": "Entailment"
    },
    "a6e81477-f863-4a83-9007-fd2f1f5c6781": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "Breast Cancer and Ovarian/ Peritoneal Cancer patients in the primary trial undergo the same intervention.",
        "Label": "Entailment"
    },
    "2312576f-7c8d-4fcd-80e8-42cf3d81dd04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "cohort 1 of the primary trial recieves higher doses of Eribulin than cohort 2 patients receive of Docetaxel",
        "Label": "Contradiction"
    },
    "a8268e5e-d758-4dcf-8dd9-78c2016bc7f6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "Both the primary trial cohorts receive pre-operative Dexamethasone",
        "Label": "Entailment"
    },
    "1bd849aa-409c-4214-a930-4d187a645466": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, at the same frequency, with the only difference being that cohort 1 also recieves PD-0332991 once weekly.",
        "Label": "Contradiction"
    },
    "5578e4a3-95d9-4803-8d13-b9c0276f92e0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency",
        "Label": "Entailment"
    },
    "5e92a3fd-5ffa-49db-9978-897321839068": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a dayand recieves weekly antineoplastic chemotherapy.",
        "Label": "Contradiction"
    },
    "539bf07d-199d-4c9b-af16-5f314962bcfc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the patients first of kin.",
        "Label": "Contradiction"
    },
    "0a266c52-2a4e-4aed-a04c-85c148f2cd41": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "the Bevacizumab cohort of the primary trial produced better results than the Bevacizumab + Capecitabine cohort.",
        "Label": "Contradiction"
    },
    "4e5a04a1-2513-472b-b2a7-891d68a3b549": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "11% more Participants in the ER-positive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group",
        "Label": "Entailment"
    },
    "3ab9a40f-bbd8-43ed-a468-7fdbe3d9ce19": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "None of the primary trial patients in cohorts 1 or 2 showed discernible pattern for expression of the set of 40 evaluated genes",
        "Label": "Entailment"
    },
    "7d60c7dd-fb79-4e95-a662-32de2036683f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, both from cohort 2.",
        "Label": "Contradiction"
    },
    "9d9fc91e-b6a2-4ab8-bb28-a0a182574d90": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "Sunitinib was administered orally every day, to every patient in the primary trial for the entire duration of the study.",
        "Label": "Entailment"
    },
    "c43d1ac6-f3d2-44f6-870d-fb91f3365c5b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "the primary trial patients in The paced respiration intervention group suffered more Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events on average than patients in the The fast, shallow respiration group.",
        "Label": "Contradiction"
    },
    "95cb9c0a-0725-4108-aebb-f114f77b577c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "less than half of the primary trial participants had a Reduction in circulating tumor cells Following High-dose Chemotherapy With Purged Autologous Stem Cell Products",
        "Label": "Entailment"
    },
    "8c07a493-66a5-4728-ae22-d6c45b2215a8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg to 37.5 mg of sunitinib daily, whereas cohort 2 recieves 10 mg/kg of Bevacizumab",
        "Label": "Entailment"
    },
    "9340e38d-37ce-4634-9f36-a747f964441c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "All the primary trial candidates must have a HER2 positive tumor confirmed by IHC 3+, aswell as Requiring considerable assistance and frequent medical care",
        "Label": "Contradiction"
    },
    "fa6115aa-a765-4d03-9fd0-61c97d5e282f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "all participants in the primary trial suffered a deterioration in cognitive function, particularly those in the Ovarian Function Suppression group",
        "Label": "Contradiction"
    },
    "5a916856-536f-444d-87e7-1b2c032c0656": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "at least one patient treated with GTx-024 1mg in the primary trial gained over 10 kilos of Lean body Mass.",
        "Label": "Entailment"
    },
    "26145056-fdfd-4f2d-909e-be84fc53ede8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "Patients receiving the placebo intervention in the primary trial were twice as likely to experience emesis as patients receiving Aprepitant.",
        "Label": "Entailment"
    },
    "8367e2fc-f384-43c0-af4e-d4ec41281b2e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "Most patients in cohort 1 of the primary trial suffered adverse events, the inverse is true in cohort 2.",
        "Label": "Contradiction"
    },
    "e2979c27-0eb6-487d-a940-646685e1934b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "The difference between intervention one and two of the primary trial is that intervnetion 1 uses pIHGC, and intervention 2 uses stantdard GP.",
        "Label": "Entailment"
    },
    "5abfa152-2c23-40b4-ba00-b28336b8b8b5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the health professionals conducting the trial.",
        "Label": "Entailment"
    },
    "251e979f-a7ba-4dea-afb7-01b9501ec7cf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "96 participants from the Ketorolac 30 mg group of the primary trial experienced Recurrence-free Survival compared to the 67 from the NaCl 0.9% 3mL group",
        "Label": "Contradiction"
    },
    "5e5253e5-fd72-4f2b-84ba-b370545cd182": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but 0 cases of Pancytopenia.",
        "Label": "Contradiction"
    },
    "5e301f1c-087e-4ca4-b679-cc229d1c0d27": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg less of Durva in their monthly injections compared to cohort 2.",
        "Label": "Contradiction"
    },
    "0967b501-90dd-4ba4-bebc-8db1e9695431": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": " Alzheimer's patients are not eligible for the primary trial",
        "Label": "Entailment"
    },
    "8101ccf6-e6f4-43ba-b22f-9a13e2ddd279": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group and had more participants in it",
        "Label": "Contradiction"
    },
    "86ed4db6-24fe-4a88-ba9b-6be3f98e0525": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "The LBH589 With Capecitabine cohort of the primary trial produced worse results than the LBH589 and Lapatinib cohort",
        "Label": "Contradiction"
    },
    "d71c6377-89da-457d-acbc-827be4ddb8e5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "There was one psychiatric adverse event in the primary trial, which affected less than 10% of patients",
        "Label": "Entailment"
    },
    "15d7d028-69c2-4e01-b85c-cff568f34cc1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "anorexic patients are eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "fdadf425-1eaf-4e63-b034-29afcbe48baf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "The only AE recorded in the primary trial was Stomatitis.",
        "Label": "Contradiction"
    },
    "afdafe17-63a8-4fca-b923-a2bb964493d1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial",
        "Label": "Entailment"
    },
    "81521795-13b4-46d4-a03e-51ab823e9756": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "Both interventions in the primary trial include trastuzumab",
        "Label": "Entailment"
    },
    "593bde37-5962-441b-ac10-dbe3120cec99": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "less than 5% of patients in the primary trial suffered Aes",
        "Label": "Contradiction"
    },
    "b6902408-8d60-438b-bb38-416d4a4d76fb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "None of the primary trial candidates have to perfom regular exercise as part of the intervention",
        "Label": "Entailment"
    },
    "2c4acb3d-7009-4a19-ac0e-703a96740738": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention",
        "Label": "Entailment"
    },
    "78aec7ae-20b1-413b-9cb7-9757274ff1aa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "Morbidly obese patients are eligible for the primary trial.",
        "Label": "Entailment"
    },
    "ffacecd7-caae-434a-866d-a3a25d4f00ac": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by transendocardial injection.",
        "Label": "Entailment"
    },
    "7482499c-6836-4f68-83f4-4af09b14d566": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "There were no deaths or Hospitalizations in cohort 2 of the primary trial",
        "Label": "Entailment"
    },
    "a0d99371-52e5-4d30-81d5-ad65feba2e4e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients with measurable tumors in both breasts are excluded from the primary trial",
        "Label": "Entailment"
    },
    "47bcd1c5-f95d-4e21-a999-4bd220c5b940": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "Every patient in the primary trial is required to swallow a capsule of Vorinostat daily during radiation therapy",
        "Label": "Entailment"
    },
    "1943100e-196d-4022-a38a-9ae0dd816294": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "The difference between intervention one and two of the primary trial is that intervnetion 1 uses higher doses of radioactive Tc99M sulfur colloid  than intervention 2.",
        "Label": "Contradiction"
    },
    "f8e8c733-3fc0-4699-814f-b5d505c71435": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg of sunitinib daily, whereas cohort 2 recieves 90 mg/m^2 paclitaxel",
        "Label": "Contradiction"
    },
    "dfea11ab-1a3f-4a76-9fae-96d486f76e10": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "Patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (MI), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial",
        "Label": "Entailment"
    },
    "74308ad0-4b9d-4632-9580-5e280dedbc77": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "patients of any gender can be eligible for both phases of the primary trial if they have evidence of a ER negative breast cancer.",
        "Label": "Contradiction"
    },
    "1cda1a1d-3ca1-4838-9054-bcab763bb5d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "All of the Aes recorded for cohort 1 of the primary trial are related to mental health",
        "Label": "Contradiction"
    },
    "9228fe22-ca97-4ca9-ad78-f8dba1ac27b0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "Patients with a histologically/cytologically confirmed diagnosis of a resectable Non-small cell lung breast cancer or Small cell lung cancer are eligible for the primary trial",
        "Label": "Contradiction"
    },
    "aecd2958-c3b4-4d87-82f1-07add215b1e8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "cohort 1 of the primary trial receive pre-operative Dexamethasone, whereas cohort 2 recieves Dexamethasone 2 hours after the operation.",
        "Label": "Contradiction"
    },
    "590f240e-7499-432e-aa3c-f54eda69ed46": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will need to commit to abstinence for the entire study period ",
        "Label": "Contradiction"
    },
    "c8235719-3fd8-43e9-8ba6-d99393220240": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "There are no conditions on mental mental health, bodyweight, age, Karnofsky/ECOG score or previous treatments that need to be met in order to be eligible for the primary trial ",
        "Label": "Contradiction"
    },
    "282c18a2-64b1-47cf-8563-db8db40dadb6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, and all undergo a SPECT scan.",
        "Label": "Entailment"
    },
    "f4e0551c-44e9-44f1-9a50-c65075a51715": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "There are no conditions on hepatic function for participants of the primary trial",
        "Label": "Contradiction"
    },
    "ea1d804d-bac9-4ebd-a6bd-0705c988927f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "The the primary trial intervention section does not outline a treatment cycle or any description of the treatment",
        "Label": "Contradiction"
    },
    "17413685-69fd-453f-af49-29982a6c95b6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "Participants in cohort 1 of the primary trial are administered with Pneumococcus vaccine and those in cohort 2 are administered an Influenza vaccine.",
        "Label": "Contradiction"
    },
    "e78805f7-1b81-4cd9-a3c7-591886fd5d70": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "Paclitaxel is only used in the cohort 1 intervention of the primary trial, whereas cohort 2 is administered fulvestrant instead",
        "Label": "Contradiction"
    },
    "42857f32-4798-4767-a0c7-f74cdcab7a9b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary trial receive 4 different drugs throughout the study duration, with a maximum dose of 100 mg/m^2",
        "Label": "Contradiction"
    },
    "9c2adaba-1ac9-4a7c-a710-14ac7d2056fd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "Neither cohort of the primary trial recieves any counselling, risk assessment or CBT in the interventions.",
        "Label": "Contradiction"
    },
    "577c7755-64ae-4b78-bbe3-627cef6e3ece": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "More than 42 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months after the surgery",
        "Label": "Contradiction"
    },
    "5b13bca4-0354-4579-a868-d007bef0dbe1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "The Neratinib group of the primary trial had a lower rate of iDFS than the placebo group",
        "Label": "Contradiction"
    },
    "623db2b4-6824-42e4-9ad6-39cf3bf14dab": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a day.",
        "Label": "Entailment"
    },
    "a793df3f-fa04-4d48-a2c6-006589d52e84": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "On average both cohorts of the primary trial suffered a deterioration in cognitive function, however this was not the case for all patients",
        "Label": "Entailment"
    },
    "75961bc5-20b9-4161-83e0-a59429ce18e9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "Over 50% of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril",
        "Label": "Entailment"
    },
    "85d61aaf-5255-4203-9ccf-f9c3da7a352e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "Patients who's Metastasis cannot be measured, or who's Cancer has not spread to other parts of the body are not eligible for the primary trial",
        "Label": "Entailment"
    },
    "22384b11-eb42-42da-86b3-dfed559ebb77": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "Only 2 patients in the primary trial did not have Recurrence-free Survival",
        "Label": "Entailment"
    },
    "0c73bdd4-7244-433c-8b5e-bf335f21701c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "There were severalpsychiatric adverse event in the primary trial, including an eating disorder and Schizophrenia",
        "Label": "Contradiction"
    },
    "b358fb9c-1152-4e1a-88eb-743e965d58fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "Patients with a history of severe anaphylactic reactions to trastuzumab cannot take part in the primary trial.",
        "Label": "Entailment"
    },
    "fa586070-5821-4a70-9812-9d7c6e5df330": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "5 patients in the primary trial suffered 3 or more adverse events",
        "Label": "Contradiction"
    },
    "8b9a4f04-25f6-45d2-a4fe-52e5bd3d22de": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks, and over 130 mg of PDR001 every other week.",
        "Label": "Contradiction"
    },
    "851e1a1b-0b8e-4aef-a7e3-f06c036fe537": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "cohort 1 of the primary trial is administered 0.035 mg of ALT-801 less than cohort 2",
        "Label": "Contradiction"
    },
    "b25a8f34-96ce-4ea1-a140-bf5b0ffe7f52": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "Neither cohort of the primary trial recieves any drugs, radiotherapy or CBT in the interventions.",
        "Label": "Entailment"
    },
    "b9074beb-a639-46ba-966b-b0db266efffc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "The the primary trial intervention section dose not describe the method of administration, dosage or cycle.",
        "Label": "Entailment"
    },
    "017ff04d-5509-4f54-863c-10201351e15d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "several patients with Normal Vitamin D Levels in the primary trial showed discernible pattern for expression of the set of 40 evaluated genes.",
        "Label": "Contradiction"
    },
    "25551d37-108d-497a-8e75-825d8d707190": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients with measurable bilateral breast cancer are eligible for the primary trial",
        "Label": "Contradiction"
    },
    "5261c924-d9ef-43ed-8f2a-6c5b1552cc62": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will have to meet some additional requirements.",
        "Label": "Entailment"
    },
    "b5e896cf-e971-4fac-8dc6-a19e2c2d0a72": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "There are no conditions on Life expectancy, pregnancy or age for participants of the primary trial",
        "Label": "Entailment"
    },
    "2bf9e0d9-1195-4c03-b2bc-d491ff1cd174": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "36.36% of the primary trial patients suffered an increase in Blood bilirubin.",
        "Label": "Contradiction"
    },
    "523d79a3-ee67-4b2a-a1cb-20ed4ed45dc6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "49.2% more Participants in the dalotuzumab 20 mg/kg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group",
        "Label": "Contradiction"
    },
    "25cbaa44-4715-417b-9bd0-12fef06053b8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "less than 10 patients in the primary trial suffered Aes",
        "Label": "Entailment"
    },
    "5e6797ef-370c-4b35-9e1d-37e694b538a6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "25% of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression  ",
        "Label": "Contradiction"
    },
    "28a88ea8-4cea-404c-9ad7-cb1be9c19d7f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "Paclitaxel is not used in either of the primary trial interventions",
        "Label": "Entailment"
    },
    "44412911-1f34-4841-a795-86eed5a209d7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "All Infections and Fever cases in the primary trial were for patients in cohort 1.",
        "Label": "Contradiction"
    },
    "505ccc8c-b07a-4902-b8c3-4d3b4891779a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "Patients in the primary trial will need to receive several injections",
        "Label": "Entailment"
    },
    "4adbcbcc-ae43-46af-a072-815d1e788f29": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "patients diagnosed with tumors positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification are excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "10f7c7cf-b7e2-4d21-8870-1fdbcc7937f5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "In the primary trial the placebo intervention and the Memantine intervention are administered at the same frequency for the same duration of time.",
        "Label": "Entailment"
    },
    "bd5d8368-5c1d-41b8-9fb3-f174da18744f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "All patients treated with GTx-024 1mg in the primary trial gained Lean body Mass over a 4 month period",
        "Label": "Contradiction"
    },
    "574106ef-1b9c-4540-a89f-5100a9bbe798": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "African-american patients can participate in the primary trial, but they must reside in the state of texas for the duration of the study.",
        "Label": "Contradiction"
    },
    "9d94e597-591d-409e-a8e2-b205a83533a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy",
        "Label": "Entailment"
    },
    "7e271bbd-26e8-422e-be5c-54d294da815a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "Patients diagnosed stage 4 invasive carcinoma of the breast that is estrogen and/or progesterone receptor positive, and are considering AI therapy are eligible for the primary trial.",
        "Label": "Contradiction"
    },
    "6e4be816-3da7-4def-ab23-2a4fda805cd0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "laser-assisted fluorescence angiography and Lateral radial incisions are used for both interventions in the primary trial.",
        "Label": "Contradiction"
    },
    "90cecb95-9f89-4747-81c3-96545edaf3f4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "No two patients in the primary trial suffered the same type of adverse event.",
        "Label": "Entailment"
    },
    "137bb76f-a37e-4339-af7e-f0c647a01baa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "the Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab + Capecitabine cohort.",
        "Label": "Entailment"
    },
    "b87ab44e-6cbe-4567-98ff-bd820aa7edeb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "13% of the primary trial participants with HER2- Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed Imagable HER2+ Metastases",
        "Label": "Entailment"
    },
    "e2e8bb00-df98-49c2-a81b-e18ae21516aa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by a single transendocardial injection.",
        "Label": "Contradiction"
    },
    "6b3619d3-21ea-437e-bb0f-f124cf636ca5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "the primary trial participants receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15",
        "Label": "Contradiction"
    },
    "c08aa0d8-5505-438c-b53a-934bd2ee570d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "the primary trial does not report any results for the LBH589 and Lapatinib cohort.",
        "Label": "Entailment"
    },
    "ddf4fc68-7920-4212-ac8b-7453ebeb49fb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures.",
        "Label": "Entailment"
    },
    "6af06b3f-dbbc-4679-a4a3-fe4b3757fdc0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "There are 7 more participants in cohort 2 of the primary trial than in cohort 1",
        "Label": "Entailment"
    },
    "e63ac45b-c34b-4007-820a-30202893fc6f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "There are a limited number of available places in the primary trial for patients diagnosed with Metastatic colorectal cancer that harbors the Kras or BRAF mutation .",
        "Label": "Entailment"
    },
    "29bed237-ccbb-460b-a50b-fbdc9e52fdd1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "All AE types in the primary trial affected less than 10% of patients",
        "Label": "Entailment"
    },
    "71698d59-3bbe-4e8f-85c8-bf2110727155": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "Only 4 different types of adverse events affected patients in the primary trial, all of which were in cohort 2",
        "Label": "Entailment"
    },
    "d0168033-35eb-4032-b6e5-f81d9d3a9f7a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "Patients in the primary trial that didn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t receive topical cryotherapy had worse symptoms than patients that did receive topical cryotherapy.",
        "Label": "Entailment"
    },
    "3d100b36-5765-4953-b072-b06f38b6958c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group",
        "Label": "Entailment"
    },
    "f0ca21dc-bf98-4c8b-b08e-d0821905846a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients on the waiting list.",
        "Label": "Entailment"
    },
    "52d4cfdf-7677-4f4c-8020-4f5271393df9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "Patients participating in the primary trial receive oral medication twice a day for a full month.",
        "Label": "Entailment"
    },
    "a8932849-e870-422e-a81a-1b43d9622082": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "the Ketorolac 30 mg group of the primary trial had a -6.4% Recurrence-free Survival compared to the NaCl 0.9% 3mL group",
        "Label": "Entailment"
    },
    "06a1adac-dee0-4d9b-83c6-0996391e40d0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Statement": "13 participants in the primary trial were treated with the Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine ",
        "Label": "Entailment"
    },
    "496667f2-e493-4b4e-a257-7b8de3833e8b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "The placebo and Trabectedin intervention in the primary trial are administered in the same manner, but on different days.",
        "Label": "Entailment"
    },
    "90c519e9-7981-4a72-af6a-cc032657458a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "The the primary trial intervention section requires surgical and imaging procedures.",
        "Label": "Contradiction"
    },
    "d9e7c0cc-0850-4a8e-b389-092dfdc623fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "Patients with histologically documented metastatic SCBC are excluded from the primary trial.",
        "Label": "Entailment"
    },
    "7814620b-23de-463b-8fd1-efdf51ce26b3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with ILD/DPLD within the last 3 years, with a life expectancy of 6 months would be eligible for the primary trial",
        "Label": "Contradiction"
    },
    "a60074c0-d7a6-47cc-b980-ee1c0a791f66": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "Both cohorts of the primary trial receive the same doses of Abraxane",
        "Label": "Entailment"
    },
    "d9d506ef-20ed-44e2-9809-07cb0772535b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "All Infections and Infestations cases in the primary trial were for patients in cohort 1.",
        "Label": "Entailment"
    },
    "1fe68175-6ac4-4439-818f-94758e6bd306": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "Patients in the primary trial that didn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions.",
        "Label": "Contradiction"
    },
    "fac10570-e1ed-4b0a-b847-55eb25265d25": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but no cases of Pancytopenia.",
        "Label": "Entailment"
    },
    "152fc619-bbb0-40ff-aa3e-5722f62f6a84": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, however the intervention for cohort one carries on for two weeks longer.",
        "Label": "Contradiction"
    },
    "228308ea-2483-4311-a975-ca974ff797c6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "Nobody taking part in the primary trial suffered a UTI",
        "Label": "Contradiction"
    },
    "17660aaf-9218-4119-b00c-f3b863718e97": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but had an additional Collaborative Care Intervention",
        "Label": "Contradiction"
    },
    "36cbd8dd-9c77-496c-ab43-af1942c86339": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "Both cohorts of the primary trial receive the same doses of Abraxane and Carboplatin",
        "Label": "Contradiction"
    },
    "50dae016-a6b4-4ee6-a66a-bf35587cd835": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "On average patients from the primary trial survive over 2 years, however at least one patient from both cohorts died in under 2 years.",
        "Label": "Entailment"
    },
    "ef2af81d-e19c-49c9-8ff0-309b87eb6f38": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "the primary trial only has a single adverse event recorded for its patient cohort.",
        "Label": "Entailment"
    },
    "2e42ac97-e353-4bbc-b61e-391e0c092689": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg/kg less of Durva in their bi-weekly IV infusions compared to cohort 2.",
        "Label": "Entailment"
    },
    "4f1bafd9-361f-4981-b6fd-46af736141b4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "The the primary trial intervention section does not outline a treatment cycle or a description of irradiation doses.",
        "Label": "Entailment"
    },
    "c91a6c5a-27f1-4e7b-8f91-34e3d2236e8b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "On average patients from the primary trial survive over 2 years, over 50 patients from each cohort survived more than 24 months",
        "Label": "Contradiction"
    },
    "0bb34f7b-d21a-4057-876a-25c722e6d50e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "97% of patients in the primary trial did not experience any Adverse Events",
        "Label": "Contradiction"
    },
    "9562c377-c748-46d7-a5f2-eb492d20e477": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "there were 0 cases of Hypertension, Dehydration and Dyspnea in either cohort of the primary trial",
        "Label": "Entailment"
    },
    "1e24905e-7bf9-4a79-8157-8948f108ecb7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "Neiter of the primary trial cohorts receive any invasive surgery or Neratinib ",
        "Label": "Entailment"
    },
    "520f44e8-b74b-44a6-a7cf-496275847af1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "Both cohorts of the primary trial recorded 0 Aes",
        "Label": "Entailment"
    },
    "0c902de2-30b5-4ab8-9739-70be987d043a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "25% of cohort 2 patients in the primary trial suffer Increased pleural effusion",
        "Label": "Entailment"
    },
    "d1d5671f-79dd-4fd3-a4aa-b5f81d8a944f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial ",
        "Label": "Contradiction"
    },
    "d0212d75-c952-4ad3-ae36-bbf675eae985": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "Over 50% of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril",
        "Label": "Contradiction"
    },
    "61a6a476-9283-4cde-89e7-5f1405f690c1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "Patients participating in the primary trial receive 100 mg/m2 oral lapatinib twice a day for a full month.",
        "Label": "Contradiction"
    },
    "fabf3f7a-48df-4940-93e2-8cbe976c4246": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "there were 0 cases of Hypertension, Edema and Dyspnea in either cohort of the primary trial",
        "Label": "Contradiction"
    },
    "5dea6bbb-13c3-470c-98a6-3879f17de8c7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "the primary trial reports the total Number of Participants Analyzed in the study, but does not report the number of participants in each cohort.",
        "Label": "Contradiction"
    },
    "c3f4b547-8d11-42ba-800c-7ccbe1283741": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for all cohorts of the primary trial",
        "Label": "Contradiction"
    },
    "451c8e9e-03c1-4b7a-9b84-5129c5623f1b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "candidates for the primary trial must have breast cancer and require hormonal treatment.",
        "Label": "Entailment"
    },
    "b6b719ca-e7f3-4254-a1a0-2946acbcd2fd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "The AZD0530 175 mg group of the primary trial experienced a greater reduction in primary tumour diameter than the Zoledronic Acid 4 mg group.",
        "Label": "Contradiction"
    },
    "b3f59657-9278-41be-b740-433b0d38fdd5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "Patients with TX NX MX, T0 NX M0 or T1 N1 M1 tumors are eligible for the primary trial",
        "Label": "Contradiction"
    },
    "bcc9a793-5002-4cd9-a5b7-af5a1ceca35a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "candidates for the primary trial must have colon cancer and be unresponsive to previous hormonal treatments.",
        "Label": "Contradiction"
    },
    "05530068-7a95-46f6-88d2-84e53ee2ff35": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "General symptoms are the most common AE recorded in the primary trial",
        "Label": "Entailment"
    },
    "f0f8a0a6-1148-4592-a9b4-27c005038900": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary trial receive 4 different drugs throughout the study duration.",
        "Label": "Entailment"
    },
    "2cde3c46-f21a-4177-afc8-94f851854b98": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "There was at least 1 recorded gastro-intestinal adverse event in the primary trial",
        "Label": "Entailment"
    },
    "b3679900-ab99-4a84-83e0-fc1122a43beb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the month before study entry are excluded from the primary trial.",
        "Label": "Entailment"
    },
    "b9b69888-f771-4a3a-b6f0-825510997cca": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "cohort 1 of the primary trial is administered less than half the dose of ALT-801 as cohort 2",
        "Label": "Entailment"
    },
    "6d7c7740-c399-4d73-82c8-2ef0d4739341": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "Cohort 1 of the primary trial did not report any Aes",
        "Label": "Entailment"
    },
    "fe6baecc-71eb-4b15-ba15-66d57539c702": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "The same perecentage of patients suffered adverse events in both cohorts of the primary trial",
        "Label": "Contradiction"
    },
    "b581bb7b-6aaa-4c8a-81a0-c5e6a58ebcdf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The patient with the longest PFS in the primary trial survived 3.5 months without disease progression or death ",
        "Label": "Entailment"
    },
    "f9e4988c-a325-40bc-8220-e7d0c404fd37": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "None of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort",
        "Label": "Entailment"
    },
    "ce40b0b9-d8d4-45f4-a2dc-4adb8e7103ac": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2.",
        "Label": "Entailment"
    },
    "0c27bcc9-3108-4d4a-901a-22718c22d288": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "The majority of patients in the primary trial experienced complete response by week 24.",
        "Label": "Contradiction"
    },
    "464e2cd9-6c59-4692-a3fc-083c374f4a5c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "Both interventions in the primary trial include the same dose of Paraplatin",
        "Label": "Contradiction"
    },
    "eeb18145-fc5f-41d7-bce3-245d21000e7b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced a confirmed complete response (CR) .",
        "Label": "Contradiction"
    },
    "d921df56-8a29-45a9-bb0b-66ba14dbc193": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the last 2 years before study entry are excluded from the primary trial.",
        "Label": "Contradiction"
    },
    "006c9dd6-c568-4497-81b7-c954568a3b4a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "Breast Cancer patients in the primary trial are administered 1000 mcg/day of talazoparib whereas Ovarian/ Peritoneal Cancer patients in the primary trial receive only 25 mcg/day talazoparib instead.",
        "Label": "Contradiction"
    },
    "585b42d5-c81a-482a-a6bf-b7db6c6edcfb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention.",
        "Label": "Contradiction"
    },
    "eb088d03-7fdc-48bd-9175-0e7a9cfc7b9a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "100.0% of cohort 1 of the primary trial suffered some kind of adverse event",
        "Label": "Entailment"
    },
    "a5657dcd-1ee5-44f6-bb21-e718259c4b2e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "There were no deaths or Hospitalizations in cohort 2 of the primary trial, and only a single case of Atrial fibrillation .",
        "Label": "Contradiction"
    },
    "4bc60955-6137-4496-b780-5fb8e90dc3ed": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "maculo-papular Rash was a common adverse event for the primary trial participants.",
        "Label": "Contradiction"
    },
    "7ad6c209-8893-4a2d-963d-24666ef93a80": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures, with the exception that cohort 1 will receive a slightly higher dose of 18F-FPPRGD2.",
        "Label": "Contradiction"
    },
    "73feb437-66f3-44fd-8d9c-ab3204e6eac3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "Several recorded Aes in the primary trial occurred to cohort 1 patients",
        "Label": "Contradiction"
    },
    "9730b1a6-e9cd-4fd6-b1e4-9916b5903c63": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, 1 from each cohort.",
        "Label": "Entailment"
    },
    "2fb3af20-adda-4fee-860a-ce376d3a0bb2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "In the primary trial results there were more patients with stable disease in week 12 than week 24, but 0 patients with complete response in week 12 or 24",
        "Label": "Entailment"
    },
    "dd27a6e7-3b83-4a84-bc40-5ba39617a1c1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial, unless they are positive for either ER or PR or both.",
        "Label": "Contradiction"
    },
    "113abff0-a728-40a6-b637-8bd60a53e626": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but 8mg/kg MM-121 less than cohort 2.",
        "Label": "Entailment"
    },
    "fd0b22b0-c86d-4460-bf53-310901404ef5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "All the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3+",
        "Label": "Entailment"
    },
    "c0151b24-14ab-4837-965d-88bb8115a560": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The patient with the longest PFS in the primary trial was in cohort 1, and he survived 3.5 months without disease progression or death ",
        "Label": "Contradiction"
    },
    "5599d5d8-3a7b-41ce-a00c-6e0b609b618d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "100.0% of cohort 1 of the primary trial suffered at least 1 life-threatening adverse event",
        "Label": "Contradiction"
    },
    "84942825-f636-4dcf-af2e-172012c0cc9d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "cohort 1 of the primary trial recieves higher doses of Cyclophosphamide than Eribulin and cohort 2 patients receive higher doses of Cyclophosphamide than Docetaxel",
        "Label": "Entailment"
    },
    "27aec260-8dcc-4611-8389-dc9c10d3518d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "Results from the primary trial show that tamoxifen 32 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces the diameter of tumors by 40% on average.",
        "Label": "Contradiction"
    },
    "c09c08d5-189f-4e15-acb8-2c3cb235aaa6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "The same number of Aes were reported for both cohorts in the primary trial",
        "Label": "Entailment"
    },
    "99a6cb19-b6d8-4cb7-84e1-be559854caa6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks.",
        "Label": "Entailment"
    },
    "dcfc0053-b963-4542-ae02-228d3d2bd98e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "The Interventions in the primary trial included different medications but are administered through the same routes.",
        "Label": "Contradiction"
    },
    "eb555e01-0a12-45a1-99ad-7d7dafbe8912": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "Cohort A and B of the primary trial are administered the same Two IM injections of LD V935, at the same point in the cycle.",
        "Label": "Entailment"
    },
    "b033d45a-c039-42de-a073-3c051c6f1e3c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced either a confirmed complete response (CR) or a confirmed partial response (PR).",
        "Label": "Entailment"
    },
    "75c55f70-aa52-4794-aae7-3a355f1a76e9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for the primary trial",
        "Label": "Entailment"
    },
    "070ba2da-932a-4a62-861e-3f2c89630b4d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "Most the primary trial candidates suffered from some kind of eating disorder during the study duration",
        "Label": "Contradiction"
    },
    "76d498ce-037c-4f7e-8cbb-450d8f6019ec": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "patients of any gender can be eligible for both phases of the primary trial if they have evidence of a solid tumor that is locally advanced and/or metastatic.",
        "Label": "Entailment"
    },
    "dfd8e736-5ef2-4d36-b124-9382e72f982d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "the primary trial patients in The paced respiration intervention group experienced fewer Hot flashes per day on average than patients in the The fast, shallow respiration group.",
        "Label": "Entailment"
    },
    "e8e3fedb-075d-440e-bf2e-baec76f96cca": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "Patients with a histologically/cytologically confirmed diagnosis of a Non-small cell lung cancer or Small cell lung cancer are eligible for the primary trial",
        "Label": "Entailment"
    },
    "cd067ee2-ed1d-403b-aa50-d61a3399fda3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "after a month of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 10% reduction in the Percentage of cells with Ki67 expression  ",
        "Label": "Contradiction"
    },
    "8b50bdc1-1722-403b-a854-adeaacd02acb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "Patients with a history of severe anaphylactic reactions to herceptin, or a history of non-response to herceptin treamtents are eligible for the primary trial.",
        "Label": "Contradiction"
    }
}